Gastrointestinal uptake of FDG after N-butylscopolamine or omeprazole treatment in the rat

Annals of Nuclear Medicine

Volumn 18, Issue 7, 2004, Pages 637-640

  Yamamoto, Fumiyasu ^a   Nakada, Kunihiro ^a   Zhao, Songji ^a   Satoh, Masayuki ^a   Asaka, Masahiro ^a   Tamaki, Nagara ^a  

^a HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

FDG; N butylscopolamine; Omeprazole; PET; Physiological uptake

Indexed keywords

FLUORINE 18; FLUORODEOXYGLUCOSE; OMEPRAZOLE; SCOPOLAMINE BUTYL BROMIDE; STOMACH SECRETION INHIBITOR;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CECUM; COLON; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIET RESTRICTION; DRUG EFFICACY; ESOPHAGUS; GASTROINTESTINAL ABSORPTION; NONHUMAN; PERISTALSIS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIOACTIVITY; RAT; SMALL INTESTINE; STATISTICAL SIGNIFICANCE; STOMACH; STOMACH SECRETION;

EID: 10044275087     PISSN: 09147187     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02984589     Document Type: Article

References (17)

1. Shreve PD, Anzai Y, Wahl RL. Pitfalls in oncologic diagnosis with FDG PET imaging: physiologic and benign variants. Radiographics 1999; 19: 61-77.
2. Gordon BA, Flanagan FL, Dehdashti F. Whole-body positron emission tomography: normal variations, pitfalls, and technical considerations. AJR 1997; 169: 1675-1680.
3. Cook GJ, Maisey MN, Fogelman I. Normal variants, artifacts and interpretative pitfalls in PET imaging with 18-fluoro-2-deoxyglucose and carbon-11 methionine. Eur J Nucl Med 1999; 26: 1363-1378.
4. Engel H, Steinert H, Buck A, Berthold T, Huch Boni RA, von Schulthess GK. Whole-body PET: physiological and artifactual fluorodeoxyglucose accumulations. J Nucl Med 1996;37:441-446.
5. Kim S, Chung JK, Kim BT, Kim SJ, Jeong JM, Lee DS. Relationship between gastrointestinal F-18-fluorodeoxy-glucose accumulation and gastrointestinal symptoms in whole-body PET. Clin Positron Imaging 1999; 2: 273-280.
6. Miraldi F, Vesselle H, Faulhaber PF, Adler LP, Leisure GP. Elimination of artifactual accumulation of FDG in PET imaging of colorectal cancer. Clin Nucl Med 1998; 23:3-7.
7. Stahl A, Weber WA, Avril N, Schwaiger M. Effect of N-butylscopolamine on intestinal uptake of fluorine-18-fluorodeoxyglucose in PET imaging of the abdomen. Nuklearmedizin 2000; 39: 241-245.
8. Trenkner SW, Thompson WM. Imaging of gastrointestinal malignancies. Curr Opin Oncol 1992; 4: 736-740.
9. Cook GJ, Fogelman I, Maisey MN. Normal physiological and benign pathological variants of 18-fluoro-2-deoxyglucose positron-emission tomography scanning: potential for error in interpretation. Semin Nucl Med 1996; XXVI: 308-314.
10. Jadvar H, Tatlidil R, Garcia AA, Conti PS. Evaluation of recurrent gastric malignancy with [F-18]-FDG positron emission tomography. Clin Radiol 2003; 58: 215-221.
11. Yee J, Hung RK, Akerkar GA, Wall SD. The usefulness of glucagon hydrochloride for colonic distention in CT colonography. AJR 1999; 173: 169-172.
12. Goei R, Kessels AH, Nix M, Knipschild PG. Randomized clinical trial on the use of antispasmodic drugs in barium enema: impact on radiological practice. Eur J Radiol 2000; 36: 32-35.
13. Cittadini G, Sardanelli F, De Cicco E, Casiglia M, De Cata T, Parodi RC. Compared effect of a genetically engineered glucagon and hyoscine W-butylbromide on double-contrast barium meal study. Eur Radiol 1998; 8:449-543.
14. Lind T, Cederberg C, Ekenved G, Haglund U, Olbe L. Effect of omeprazole-a gastric proton pump inhibitor-on pentagastrin stimulated acid secretion in man. Gut 1983; 24: 270-276.
15. Yamamoto O, Okada Y, Okabe S. Effects of a proton pump inhibitor, omeprazole, on gastric secretion and gastric and duodenal ulcers or erosions in rats. Dig Dis Sci 1984; 29: 394-401.
16. Maton PN, Vakil NB, Levine JG, Hwang C, Skammer W, Lundborg P. Esomeprazole Study Investigators. Safety and efficacy of long term esomeprazole therapy in patients with healed erosive oesophagitis. Drug Saf 2001; 24: 625-635.
17. Richter JE, Kahrilas PJ, Johanson J, Maton P, Breiter JR, Hwang C. Efficacy and safety of esomeprazole compared with omeprazole in GERD patients with erosive esophagitis: a randomized controlled trial. Am J Gastroenterol 2001; 96: 656-665.